These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 9174547

  • 1. Frequency and causes of refractoriness in multiply transfused patients.
    Legler TJ, Fischer I, Dittmann J, Simson G, Lynen R, Humpe A, Riggert J, Schleyer E, Kern W, Hiddemann W, Köhler M.
    Ann Hematol; 1997 Apr; 74(4):185-9. PubMed ID: 9174547
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. HPA antibodies in Algerian multitransfused patients: Prevalence and involvement in platelet refractoriness.
    Brouk H, Bertrand G, Zitouni S, Djenouni A, Martageix C, Griffi F, Kaplan C, Ouelaa H.
    Transfus Apher Sci; 2015 Jun; 52(3):295-9. PubMed ID: 25620758
    [Abstract] [Full Text] [Related]

  • 4. Use of HLA- and HPA--matched platelets in alloimmunized patients.
    Kekomäki R.
    Vox Sang; 1998 Jun; 74 Suppl 2():359-63. PubMed ID: 9704468
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Efficacy of leukocyte-depleted platelet concentrates for prevention of HLA-alloimmunization in patients with frequent platelet transfusions: a prospective multi-institutional study using a polyester platelet filter].
    Handa M, Ikeda Y, Kurata Y, Tsubaki K, Horiuchi A, Furihata K, Kimura Y, Toyama K, Takamoto S, Tsukimoto I.
    Rinsho Ketsueki; 1992 Apr; 33(4):451-60. PubMed ID: 1602608
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial.
    van Marwijk Kooy M, van Prooijen HC, Moes M, Bosma-Stants I, Akkerman JW.
    Blood; 1991 Jan 01; 77(1):201-5. PubMed ID: 1984797
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management.
    Panch SR, Guo L, Vassallo R.
    Blood Rev; 2023 Nov 01; 62():101135. PubMed ID: 37805287
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Platelet transfusion refractoriness associated with HPA-1a (Pl(A1)) alloantibody without coexistent HLA antibodies successfully treated with antigen-negative platelet transfusions.
    Pappalardo PA, Secord AR, Quitevis P, Haimowitz MD, Goldfinger D.
    Transfusion; 2001 Aug 01; 41(8):984-7. PubMed ID: 11493728
    [Abstract] [Full Text] [Related]

  • 18. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study.
    Sintnicolaas K, van Marwijk Kooij M, van Prooijen HC, van Dijk BA, van Putten WL, Claas FH, Novotny VM, Brand A.
    Blood; 1995 Feb 01; 85(3):824-8. PubMed ID: 7833483
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.